The role of inflammation in the pathogenesis of lung cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 9, 2011, Pages 1127-1137

  Cho, William C S ^a   Kwan, Chung K ^a   Yau, Stephen ^a   So, Peter P F ^a   Poon, Patricia C M ^a   Au, Joseph S K ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Cytokine; Inflammation; Inflammatory mediator; Lung cancer; Nuclear factor kappa B (NF B); Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; C REACTIVE PROTEIN; CADHERIN; CADHERIN 13; CARRIER PROTEIN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ERLOTINIB; FIBRINOGEN; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY INTERLEUKIN 2; NEW RAS EFFECTOR 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; SILTUXIMAB; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CELL MIGRATION; CHRONIC INFLAMMATION; DRUG MEGADOSE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MACROPHAGE; METASTASIS; NEUTROPHIL; NONHUMAN; PNEUMONIA; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VIRUS INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 80051709460     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.599801     Document Type: Review

References (102)

1. Jermal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007;15:2373-80
3. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33 This is a landmark study reporting the association of chronic inflammation and cancer.
4. Thorsteinsdottir S, Gudjonsson T, Nielsen OH, et al. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat Rev Gastroenterol Hepatol 2011;published online 7 June 2011; doi:10.1038/nrgastro.2011.96
5. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-16
6. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83
7. Wan SG, Taccioli C, Jiang Y, et al. Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression. Int J Cancer 2011;129:331-45
8. de Martel C, Plummer M, Parsonnet J, et al. Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract. Br J Cancer 2009;100:194-9
9. Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011;25:634-45
10. Polk DB, Peek RM Jr. Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer 2010;10:403-14
11. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol 2011;60:106-17
12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44
13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44 This is an extensive review discussing cancer-related inflammation.
14. Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev 2011;240:141-59
15. Kundu JK, Surh YJ. Inflammation: Gearing the journey to cancer. Mutat Res 2008;659:15-30
16. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97
17. Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 2011;71:1710-20
18. Losa D, Chanson M, Crespin S. Connexins as therapeutic targets in lung disease. Expert Opin Ther Targets 2011;published online 17 May 2011; doi:10.1517/14728222.2011.584875
19. Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:29S-55S
20. Engels EA. Inflammation in the development of lung cancer: Epidemiological evidence. Expert Rev Anticancer Ther 2008;8:605-15
21. Houghton AM, Mouded M, Shapiro SD, Common origins of lung cancer and COPD. Nat Med. 2008;14:1023-4 This is an extensive review discussing lung cancer and chronic inflammation.
22. Moghaddam SJ, Li H, Cho SN, et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009;40:443-53
23. Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: Needs and opportunities for integrated research. J Natl Cancer Inst 2009;101:554-9
24. Oh SS, Chang SC, Cai L, et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer 2010;127:2169-82
25. Goldkorn T, Filosto S. Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke. Am J Respir Cell Mol Biol 2010;43:259-68
26. Schwartz L, Guais A, Chaumet-Riffaud P, et al. Carbon dioxide is largely responsible for the acute inflammatory effects of tobacco smoke. Inhal Toxicol 2010;22:543-51
27. Cheng CY, Hsieh HL, Sun CC, et al. IL-1beta induces urokinase-plasminogen activator expression and cell migration through PKCalpha, JNK1/2, and NF-kappaB in A549 cells. J Cell Physiol 2009;219:183-93
28. Cheng CY, Kuo CT, Lin CC, et al. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol 2010;160:1595-610
29. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010;17:3297-302
30. Gougeon ML, Chiodi F. Impact of gamma-chain cytokines on T cell homeostasis in HIV-1 infection: Therapeutic implications. J Intern Med 2010;267:502-14
31. Jin GH, Hirano T, Murakami M. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int Immunol 2008;20:783-9
32. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010;107:11906-11 This study introduced an improved IL-2 immunotherapy approach.
33. Gillies SD, Lan Y, Hettmann T, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85 This study used gene modification of immunocytokine to retain antitumor activity with low toxicity.
34. Gocheva V, Wang HW, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24:241-55
35. Chi X, Tai HH. Interleukin-4 up-regulates 15- hydroxyprostaglandin dehydrogenase (15- PGDH) in human lung cancer cells. Exp Cell Res 2010;316:2251-9
36. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila) 2011;4:51-64
37. Huang WL, Yeh HH, Lin CC, et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: A biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 2010;9:309
38. Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481-94
39. Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010;107:15535-40
40. Eikawa S, Ohue Y, Kitaoka K, et al. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 2010;185:6734-40
41. Hsu YL, Hung JY, Ko YC, et al. Phospholipase D signaling pathway is involved in lung cancer-derived IL- 8 increased osteoclastogenesis. Carcinogenesis 2010;31:587-96
42. Miotto D, Cascio NL, Stendardo M, et al. CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 2010;69:355-60
43. Kuo PL, Hung JY, Huang SK, et al. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol 2011;186:1521-30
44. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine Growth Factor Rev 2010;21:413-23
45. Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114:357-9
46. Ye ZJ, Zhou Q, Gu YY, et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 2010;185:6348-54
47. Chen X, Xie Q, Cheng X, et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010;101:2384-90
48. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: Perspectives in SCLC. Expert Opin Investig Drugs 2009;18:481-90
49. Pfeiffer M, Hartmann TN, Leick M, et al. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer 2009;100:1949-56
50. Minamiya Y, Saito H, Takahashi N, et al. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2010;68:466-71
51. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011;70(Suppl 1):i104-8
52. Greqorc V, De Braud FG, De Pas TM, et al. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res 2011;17:1964-72 This clinical trial investigated the combination of chemotherapy and immunotherapy.
53. Probst BL, Liu L, Ramesh V, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010;17:1645-54
54. Bai L, Xu S, Chen W, et al. Blocking NF-kappaB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis 2011;16:45-54
55. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8
56. Ogiwara H, Kohno T, Nakanishi H, et al. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene 2008;27:4788-97
57. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008;105:252-7
58. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signaling in a mouse model of lung adenocarcinoma. Nature 2009;462:104-7 This study described an important signaling pathway in lung carcinogenesis.
59. Crescenzi E, Pacifico F, Lavorgna A, et al. NF-kappaB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells. Oncogene 2011;30:2707-17
60. Tauler J, Mulshine JL. Lung cancer and inflammation: Interaction of chemokines and hnRNPs. Curr Opin Pharmacol 2009;9:384-8
61. Tauler J, Zudaire E, Liu H, et al. HnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res 2010;70:7137-47
62. Cho WC. Recent progress in genetic variants associated with cancer and their implications in diagnostics development. Expert Rev Mol Diagn 2010;10:699-703
63. Landvik NE, Hart K, Skaug V, et al. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 2009;30:1186-92
64. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y. IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population. J Thorac Oncol 2010;5:299-304
65. Hildebrandt MA, Komaki R, Liao Z, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS ONE 2010;5:e12402
66. Truong T, Sauter W, McKay JD, et al. International Lung Cancer Consortium: Coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis 2010;31:625-33 This study identified the potential lung cancer susceptibility variants.
67. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007;150:829-31
68. Blanco D, Vicent S, Fraga MF, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 2007;9:840-52
69. Williams AE, Perry MM, Moschos SA, et al. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 2008;36:1211-15
70. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706
71. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506
72. Tili E, Michaille JJ, Wernicke D, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 2011;108:4908-13
73. Cho WC. MicroRNAs as therapeutic targets for lung cancer. Expert Opin Ther Targets 2010;14:1005-8
74. Gibbons DL, Rizvi ZH, Kurie JM. The role of microRNAs in lung cancer development, progression, and metastasis. In: Cho WC. editor. MicroRNAs in cancer translational research. New York: Springer; 2011. p. 73-89
75. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008;43:374-9
76. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437-44
77. Sahni A, Simpson-Haidaris PJ, Sahni SK, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2008;6:176-83
78. Cremona M, Calabro E, Randi G, et al. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 2010;116:1326-35
79. Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 2010;102:1731-5
80. O'Dowd C, McRae LA, McMillan DC, et al. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010;5:988-92
81. Minamiya Y, Miura M, Hinai Y, et al. The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2010;31:673-9
82. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: Findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26
83. Koch A, Fohlin H, Sorenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009;4:326-32
84. Saha S, Harrison SH, Chen JY. Dissecting the human plasma proteome and inflammatory response biomarkers. Proteomics 2009;9:470-84
85. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010;14:45-55
86. Seike T, Fujita K, Yamakawa Y, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 2011;28:13-25
87. Navin N, Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011;3:31
88. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4
89. Garcia MG, Alaniz L, Lopes EC, et al. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005;29:1425-34
90. Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumors: An ECSG/EORTC study. Eur J Cancer 2005;41:702-7
91. Yang J, Amiri KI, Burke JR, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006;12:950-60
92. Choo MK, Sakurai H, Kim DH, Saiki I. A ginseng saponin metabolite suppresses tumor necrosis factor-a-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. Oncol Rep 2008;19:595-600
93. Hideshima T, Chauhan D, Kiziltepe T, et al. Biologic sequelae of IkappaB kinase (IKK) inhibition in multiple myeloma: Therapeutic implications. Blood 2009;113:5228-36
94. Jeon KI, Xu X, Aizawa T, et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA 2010;107:9795-800
95. Pandey MK, Sung B, Kunnumakkara AB, et al. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008;68:5370-9
96. Choi KC, Lee YH, Jung MG, et al. Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol Cancer Res 2009;7:2011-21
97. Wang X, Ju W, Renouard J, et al. 17-allylamino-17- demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 2006;66:1089-95
98. Wang X, Chen W, Lin Y. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochem Biophys Res Commun 2007;355:807-12
99. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74 This is a very authoritative paper discussing the hallmarks of cancer.
100. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70 This paper described the immune system's dual role in cancer.
101. Zhu Z, Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 2011;12:3
102. Flores-Santana W, Moody T, Chen W, et al. Redox-modified non-steroidal anti-inflammatory drugs as potential anti-cancer agents with the SOD mimetic nitroxide. Br J Pharmacol 2011: [Epub ahead of print]